NCT00004941View on ClinicalTrials.gov

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

94

Participants

Timeline

Start Date

July 31, 1996

Study Completion Date

July 31, 1996

Conditions

Crohn's Disease

Interventions

DRUG

monoclonal antibody cA2

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Centocor, Inc.

INDUSTRY

lead

FDA Office of Orphan Products Development

FED